RAD-x adds Medizin Center Bonn to its fast growing diagnostic imaging platform - Gilde Healthcare

RAD-x adds Medizin Center Bonn to its fast growing diagnostic imaging platform

19 april 2021

Utrecht (the Netherlands) and Mannheim (Germany) – RAD-x, the leading European diagnostic imaging practice operator and portfolio company of Gilde Healthcare Private Equity, is adding Medizin Center Bonn (MCB) to its group. MCB provides cutting-edge premier nuclear medicine- and radiology services in the region of Bonn, NRW, Germany and is an acknowledged pioneer in PET/CT diagnostics.

MCB is the next medical imaging center in Germany to join the fast growing RAD-x Group in a short time. RAD-x Group differentiates by offering the highest medical quality, hands-on support for organisational and financial growth, e.g. for the procurement of heavy equipment, and the long-term development of regional practice clusters. RAD-x expects to welcome additional radiology centers to its platform in the course of this year.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Private Equity and Venture & Growth.
Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America.
For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company CatalYm announces leadership changes to accelerate visugromab late-stage clinical development

Gilde Healthcare company CatalYm, a world-leader in neutralizing GDF-15 in cancer and cachexia, today announced changes to its executive leadership team to support its next stage of growth. The appointments of Clinton Musil as Chief...
15 september 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10 september 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer (CEO) with effect from September...
3 september 2025